Business
Senseonics Announces First Commercial Patients Using Eversense 365 Continuous Glucose Monitor (CGM) with twiist™ Automated Insulin Delivery (AID) System
twiist™ becomes the first AID system compatible with Senseonics Eversense® 365 one-year CGM GERMANTOWN, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Senseonics
About this update from Senseonics Holdings, Inc.
[{"type":"text","content":"twiist™ becomes the first AID system compatible with Senseonics Eversense® 365 one-year CGM\nGERMANTOWN, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable CGM systems for people with diabetes with Sequel MedTech, LLC, a company developing state-of-the-art insulin delivery technologies, have launched the integration of their products with the first patients having received a Sequel twiist AID system paired with the Eversense 365 CGM. The commercial launch of the integrated products provides people with type 1 diabetes a new level of flexibility and personalization in their diabetes management. Pairing twiist™ with Senseonics’ Eversense 365 is the first time the world’s only One Year CGM system has been integrated with an AID, representing a major milestone in holistic, long-term diabetes management by reducing the need for regular sensor changes and re-pairing, while maintaining exceptional accuracy. As the only implantable CGM available, Eversense 365 offers patients a truly differentiated CGM experience, providing one year of exceptionally accurate monitoring with minimal interruptions. Eversense 365’s unique approach allows people to overcome common frustrations and interruptions experienced with traditional, short-term CGMs, so that patients can focus on managing their diabetes and not their CGM. The twiist AID system is the first and only system to use iiSure™ technology to directly measure the volume of insulin delivered, helping ensure accuracy and occlusion detection up to nine times faster than other AID systems. Powered by the twiist Loop algorithm, the system automatically adjusts insulin delivery based on real-time sensor readings and predicted glucose levels to reduce the burden of managing diabetes. “While our technologies are unique, our goal is the same - to improve lives and reduce complexity for patients living with diabetes,” said Tim Goodnow, President and CEO of Senseonics. “We are proud to partner with Sequel and provide the necessary glucose monitoring data to power the twiist Loop algorithm, which enables real-time insulin delivery decisions through the twiist pump. Patients and providers want reliable, long-term automated glucose readings and we’ve taken a m...